<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771756</url>
  </required_header>
  <id_info>
    <org_study_id>CH-BC-036</org_study_id>
    <nct_id>NCT02771756</nct_id>
  </id_info>
  <brief_title>The Effect of Zhen Qi Shen Capsule Combined With Yu Yi Kang on Breast Cancer and Lung Cancer Patients With Chemotherapy</brief_title>
  <official_title>Randomized, Self Controlled Study on the Effect of Oral Supplement of Zhen Qi Shen Capsule Combined With Yu Yi Kang on Breast Cancer and Lung Cancer Patients With Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to research more reasonable and safe methods of nutritional
      support to improve the nutritional status of tumor patients, which guarantees the anti-tumor
      treatment such as chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, controlled clinical trials. 300 patients were
      randomly divided into 2 groups for its own control study.

      Test group: Zhen qishen capsule (2 capsules, Bid) and Oral Supplement of Yuyikang (50g,Bid),
      a total of 150 people, are used for 42 days continuously.

      Placebo group: Zhen qishen capsule placebo (2 capsules, Bid) and Oral Supplement of Yuyikang
      placebo (50g, Bid), a total of 150 people, are used for 42 days continuously.

      The subjects were randomized to AB or BA parallely, and the two groups were given
      chemotherapy and nutrition.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight change rate</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Siderophilin change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin 1 change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>interleukin 6 change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Necrosis Factor Î± change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change status of the Gripping Power</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prealbumin Blood Examination change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Bilirubin change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin Direct change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect Bilirubin change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline Phosphatase change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Nitrogen change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte Number change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin change status</measure>
    <time_frame>6 weeks and 9 weeks after baseline.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life questionnaire(QOL-C30)</measure>
    <time_frame>At baseline,6 weeks and 9 weeks after baseline.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Scored Patient-Generated Subjective Global Assessment(PG-SGA)</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zhen qishen capsule (2 capsules, Bid) and Oral Supplement of Yuyikang (50g, Bid), a total of 150 people, are used for 42 days continuously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Zhen qishen capsule placebo (2 capsules, Bid) and Oral Supplement of Yuyikang placebo (50g,Bid), a total of 150 people, are used for 42 days continuously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>zhen qishen capsule and Oral Supplement of Yuyikang</intervention_name>
    <arm_group_label>test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>zhen qishen capsule placebo and Oral Supplement of Yuyikang placebo</intervention_name>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <arm_group_label>test group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nutrition education</intervention_name>
    <arm_group_label>test group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 18 and 70 years old

          -  Breast or lung cancer was diagnosed by pathology or cytology

          -  ECOG score: 0-2 points

          -  PG-SGA: 2-8 points, while the weight loss within 3 months less than 5%

          -  The organ function is good, with chemotherapy index. ANC is equal to or over 1.5 *
             10^9/L, PLT is equal to or over 100* 10^9/L, HGB is equal to or over 90g/L

          -  Bilirubin is equal to or less than 1.5 times of the normal upper limit, AP, AST, ALT
             is less than or equal to 2 times of normal upper limit

          -  Ccr is equal to or over 50mL/min

          -  Life expectancy is equal to or over 12 weeks

        Exclusion Criteria:

          -  Complete or incomplete intestinal obstruction

          -  A severe infection or difficult to control diabetes

          -  History of organ transplantation, or current use of immunosuppressive agents

          -  An intervention in nutritional supplements, or a metabolic disorder

          -  Parenteral nutrition must be applied

          -  Alcoholism or drug addiction

          -  Pregnancy or lactation, or women of childbearing age refuse contraception

          -  There are potential factors that interfere with the mental, psychological, family,
             social or geographical and other factors of the research project

          -  There are other diseases that may interfere with the results of this study, such as
             the second primary tumor

          -  For any other reason, the researchers were unable to complete the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng Yuan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Yuan, MD</last_name>
    <phone>00861087788528</phone>
    <email>Yuanpeng01@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Institute, Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Yuan, MD</last_name>
      <phone>86-10-87788528</phone>
      <email>Yuanpeng01@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Peng Yuan</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Nutritional support</keyword>
  <keyword>Safety</keyword>
  <keyword>Effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

